UK Pharma Co. Scores Patent For Magic Mushroom Treatment
Law360 (January 14, 2020, 10:04 PM EST) -- A U.K.-based mental health care company announced it has been granted a U.S. patent for a formulation that includes an active ingredient in psychedelic mushrooms, which the company is researching as a treatment for drug-resistant depression.
Compass Pathways Ltd.’s Monday statement announcing the acquisition of U.S. Patent No. 10,519,175 said the formulation includes psilocybin, the ingredient in so-called magic mushrooms. The patent also includes the use of the company’s “investigational” formulation in a therapy protocol for patients with treatment-resistant depression, according to the statement.
Compass said its therapy protocol was well-tolerated among healthy adult volunteers with support from trained therapists in...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!